Clinical Trials

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05198804 2026-03-18

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

117 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06412120 2026-03-16

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Phase 1 Active not recruiting

Ovarian Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 3 FDA

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Phase 1 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT06180356 2025-11-28

ANALLISA

30 enrolled

Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

36 enrolled 11 charts

Ovarian Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

30 enrolled

Breast Neoplasms, Ovarian Neoplasms

NCT05009082 2025-09-10

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Phase 3 Recruiting

970 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05672095 2025-05-23

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Phase 1/2 Withdrawn

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04502602 2025-05-04

iNNOVATE

18 enrolled

Ovarian Neoplasms

NCT05990192 2025-04-22

SOPRANO

42 enrolled

Ovarian Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

7 enrolled

Phase 4 Not yet recruiting

Ovarian Neoplasms, Endometrial Neoplasms

NCT06887933 2025-03-21

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

67 enrolled

Ovarian Neoplasms

NCT03891576 2025-01-17

Newton

Classical hematologyGynecologic

83 enrolled

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

67 enrolled

Ovarian Neoplasms

NCT03752216 2024-12-13

NiQoLe

Phase 4 Completed

141 enrolled

Ovarian Neoplasms

NCT04826198 2024-12-05

REVOCAN

Phase 1/2 Terminated

13 enrolled

Ovarian Neoplasms

NCT06161493 2024-10-15

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Phase 1 Withdrawn

Ovarian Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

417 enrolled

Ovarian Neoplasms

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

Breast Neoplasms, Ovarian Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

20 enrolled 42 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

19 enrolled 39 charts

Phase EARLY_PHASE1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04267939 2023-12-21

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Phase 1 Terminated

14 enrolled

Ovarian Neoplasms

NCT04284852 2023-12-15

NEOPRIMA

20 enrolled

Neoplasms, Ovarian Neoplasms

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

40 enrolled

Ovarian Neoplasms

NCT03944902 2023-11-21

BRCA

Phase 1 Terminated

1 enrolled

Ovarian Neoplasms

NCT03695380 2023-08-14

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Phase 1 Completed

77 enrolled

Ovarian Neoplasms

NCT01847274 2023-06-02

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Phase 3 Completed

596 enrolled 65 charts

Ovarian Neoplasms

NCT05749211 2023-05-16

Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer

Phase NA Unknown

59 enrolled

Ovarian Neoplasms

NCT05751629 2023-04-21

COHORT-A

41 enrolled 17 charts

Ovarian Neoplasms

NCT05641506 2022-12-07

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Phase 2 Unknown

50 enrolled

Nausea, Ovarian Neoplasms

NCT02657889 2022-12-01

TOPACIO

Phase 1/2 Completed

122 enrolled 29 charts

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01905592 2022-11-15

BRAVO

Phase 3 Terminated

216 enrolled 19 charts

Breast Neoplasms, Ovarian Neoplasms

NCT02354586 2022-09-15

QUADRA

463 enrolled 15 charts 2 FDA

Ovarian Neoplasms

NCT03955471 2022-09-10

MOONSTONE

41 enrolled 22 charts

Ovarian Neoplasms

NCT02354131 2022-08-30

AVANOVA

Phase 1/2 Completed

108 enrolled

Ovarian Neoplasms

NCT04392102 2022-08-29

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

15 enrolled

Ovarian Neoplasms

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Phase 2 Unknown

36 enrolled